TOVX Stock Risk & Deep Value Analysis
Theriva Biologics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About TOVX Stock
We analyzed Theriva Biologics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TOVX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TOVX Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Negative or inconclusive VCN-01 clinical trial results
- 📅
Failure to secure adequate funding leading to further significant dilution or operational curtailment
- 📅
Competitive therapies demonstrating superior efficacy in pancreatic cancer
Unlock TOVX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Theriva Biologics Inc (TOVX) Do?
Market Cap
$6.57M
Sector
Healthcare
Industry
Biotechnology
Employees
20
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Visit Theriva Biologics Inc WebsiteInvestment Thesis
Theriva Biologics represents a highly speculative, binary investment opportunity betting on the clinical and commercial success of its lead asset, VCN-01, in metastatic pancreatic cancer. Despite a critically fragile balance sheet, the substantial unmet medical need and regulatory tailwinds (Orphan Drug, Fast Track) provide a pathway to potentially outsized returns (10x+) if VCN-01 achieves positive Phase 2b/3 trial results and secures a significant partnership or funding.
Is TOVX Stock Undervalued?
Unlock the full AI analysis for TOVX
Get the complete DVR score, risk analysis, and more
TOVX Price Targets & Strategy
12-Month Target
$0.85
Bull Case
$10.00
Bear Case
$0.05
Entry Strategy
Extremely speculative. Consider only a very small, aggressive allocation. Accumulate on any dips below $0.15, or after a significant de-risking event such as a successful funding round or positive interim trial data.
Exit Strategy
Given the binary nature, consider taking partial profits (e.g., 50%) on any significant positive news catalysts (e.g., interim data, partnership announcement) that lead to a 200-300% surge. Implement a stop loss around $0.10 to protect against further dilution or negative trial news.
Portfolio Allocation
Less than 1% for very aggressive, high-risk tolerance portfolios.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is TOVX Financially Healthy?
Valuation
P/E Ratio
0.09
Price/Book
0.30
Does TOVX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable
Moat Sources
1 Identified
Currently, the company possesses no durable moat. Its future moat would entirely depend on the successful clinical development and regulatory approval of VCN-01, granting it temporary market exclusivity through patent protection and Orphan Drug designation.
Moat Erosion Risks
- •Clinical trial failure of VCN-01
- •Expiration of key patents or intellectual property challenges
- •Emergence of more effective or safer competitive therapies for pancreatic cancer
- •Inability to secure funding for commercialization, leading to licensing and loss of direct market control.
TOVX Competitive Moat Analysis
Sign up to see competitive advantages
TOVX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral-Bullish
Institutional Sentiment
Negative
Insider Activity (Form 4)
No significant recent activity reported (assuming no new information since last analysis).
Options Flow
Low liquidity and volume. High implied volatility due to binary nature. No unusual institutional activity detected given market cap.
Earnings Intelligence
Next Earnings
Estimated mid-May 2026 (for Q1 2026)
Surprise Probability
Low
Historical Earnings Pattern
Stock price reaction highly volatile and primarily driven by clinical trial updates, regulatory news, or financing announcements rather than traditional earnings beats/misses.
Key Metrics to Watch
Competitive Position
Top Competitor
FGEN
Market Share Trend
Not applicable; pre-revenue clinical-stage company.
Valuation vs Peers
Trades at a significant discount to clinical-stage biotech peers due to its smaller pipeline, single asset dependency, and precarious financial position, but offers potentially higher percentage upside if VCN-01 succeeds.
Competitive Advantages
- •Unique oncolytic adenovirus mechanism of action for VCN-01
- •Orphan Drug Designation for pancreatic cancer (in the EU, previously in US)
- •Fast Track Designation for metastatic pancreatic cancer (US FDA)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive TOVX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated mid-May 2026)
- •Updates on VCN-01 Phase 2b/3 trial enrollment progress
- •Potential strategic financing announcement or partnership discussions
Medium-Term (6-18 months)
- •Interim data readout from the VCN-01 Phase 2b/3 trial
- •Potential licensing or collaboration agreement for VCN-01
Long-Term (18+ months)
- •Full Phase 3 clinical trial results for VCN-01 and potential regulatory submission
- •Commercialization of VCN-01 following FDA approval (if successful)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TOVX?
- ✓
Announcement of positive interim or final data from the VCN-01 Phase 2b/3 trial
- ✓
Successful closure of a significant financing round or strategic partnership
- ✓
Stabilization or improvement in cash burn rate and cash runway projections
Bull Case Analysis
See what could go right with Premium
Competing with TOVX
See how Theriva Biologics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Theriva Biologics Inc TOVX | $6.6M | 3.5 | 0.1 | — | — | — |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Theriva Biologics Inc (TOVX)?
As of March 15, 2026, Theriva Biologics Inc has a DVR Score of 3.5 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Theriva Biologics Inc?
Theriva Biologics Inc's market capitalization is approximately $6.6M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Theriva Biologics Inc use?
TOVX is the ticker symbol for Theriva Biologics Inc. The company trades on the ASE.
What is the risk level for TOVX stock?
Our analysis rates Theriva Biologics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TOVX?
Theriva Biologics Inc currently has a price-to-earnings (P/E) ratio of 0.1. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the TOVX DVR analysis updated?
Our AI-powered analysis of Theriva Biologics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TOVX (Theriva Biologics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.